Pfizer Inc. announced the introduction of Retacrit (epoetin alfa-epbx) injection, the first available biosimilar to Procrit (epoetin alfa) and Epogen (epoetin alfa) in the U.S, at a substantial discount.
Pfizer began shipment of Retacrit to wholesalers in the U.S. on Nov. 12.
Retacrit will be introduced at a Wholesale Acquisition Cost of $11.03 per 1,000 units/mL, which is 57.1 percent below the WAC of Procrit (epoetin alfa) [$25.72 per 1,000 units/mL] and 33.5 percent below the WAC of Epogen (epoetin alfa) [$16.58 per 1,000 units/mL], its reference product.
WAC is not inclusive of discounts to payers, providers, distributors and other purchasing organizations.
The Centers for Medicare and Medicaid Services has granted two unique assigned Q codes for Retacrit: Q5105 for End-Stage Renal Disease on dialysis and Q5106 for non-ESRD.
Additionally, Retacrit qualifies for pass-through status under the hospital outpatient prospective payment system.
Retacrit is Pfizer’s third available biosimilar in the U.S. Pfizer also has an extensive biosimilars pipeline, including three biosimilars products currently accepted for review by the FDA. Pfizer has entered into an agreement with Vifor Pharma Inc. for the commercialization of Retacrit in certain channels.
Pfizer introduces biosimilar Retacrit injection in the U.S. at a substantial discount
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Table of Contents
THE CLINICAL CANCER LETTER
YOU MAY BE INTERESTED IN
More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
![](https://cdn.cancerletter.com/media/2024/07/12143220/Rejeski-and-Shouval-4x31-1.jpg)
![](https://cdn.cancerletter.com/media/2024/07/12143220/Rejeski-and-Shouval-4x31-1.jpg)
Christy Erickson was seven years old when her mom lost a three-year battle with breast cancer.
![](https://cdn.cancerletter.com/media/2024/07/12143216/Erickson-4x3-1.jpg)
![](https://cdn.cancerletter.com/media/2024/07/12143216/Erickson-4x3-1.jpg)
Two decades after uncovering the role of EGFR mutations in lung cancer, scientists are still grappling with lingering research questions.
![](https://cdn.cancerletter.com/media/2024/07/12143212/Archives-4x3-1.jpg)
![](https://cdn.cancerletter.com/media/2024/07/12143212/Archives-4x3-1.jpg)
Lei Zheng was named executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, and vice president for oncology for the University of Texas Health Science Center at San Antonio.
Mark Burkard was named director of University of Iowa Health Care Holden Comprehensive Cancer Center.